A leading supplier of accelerator-based radiopharmaceuticals and radiochemicals, serving both national and international markets. Focused on diagnostic nuclear medicine and pioneering research in therapeutic isotopes, ensuring high-quality production and global partnerships to drive innovation in healthcare.
Since the late 1980s, iThemba LABS has been recognized for supplying high-quality, accelerator-based radiopharmaceuticals and radiochemicals to both national and international markets. Our production includes short-lived SPECT radiopharmaceuticals like 123I-related products, which are distributed to over 40 nuclear medicine departments in South Africa. In 2006, we launched our first commercial PET radiopharmaceutical, 18F-FDG, followed by the introduction of the iThemba LABS 68Ge/68Ga generator in 2008.
Adhering to strict regulatory standards and current Good Manufacturing Practices (cGMP), iThemba LABS ensures the quality of its products, which serve diagnostic purposes in nuclear medicine. With a global footprint, we supply over 100 clients worldwide, delivering more than 2,100 consignments annually with a punctuality rate of over 98%, impacting the treatment of over 220,000 nuclear medicine patients in the last financial year.
iThemba LABS is also renowned for its long-lived radiochemicals, such as the ultra-high vacuum 22Na positron sources, of which we are the sole global supplier. Through strategic partnerships with reputable international companies, we maintain a robust market presence and revenue stream.
+0
Local nuclear medicine depts. & academic institutions
+0
International clients and collaborators
+0
Patients in the last financial year
Empowering People
Creating a positive environment that promotes well-being, health, and happiness for our employees and stakeholders.
Excellence Delivered
Consistently delivering world-class radiopharmaceuticals and services that positively impact healthcare globally.
Accountable Innovation
Ensuring transparency and fairness in our actions, while responsibly utilizing public resources to advance medical science.
1
Target irradiation
2
Chemical processing in hotcells
3
Preparation of final dosage in clean rooms
4
Quality control
5
Packing and distribution
Beyond production, iThemba LABS prioritizes research and development of new radiopharmaceuticals, particularly alpha-emitting isotopes for therapeutic applications, as well as the training and development of both external students and internal personnel.
Supplying over 2,100 consignments annually to more than 100 clients, iThemba LABS maintains a service delivery of over 98%.
The development of alpha-emitting radiopharmaceuticals like 211At and 225Ac, and theranostic pairs, marks iThemba LABS’ commitment to advancing therapeutic nuclear medicine for improved cancer treatments.
